APVO News and Press, Aptevo Therapeutics Inc. From 06/21/21

Gainers: Virpax Pharmaceuticals (VRPX) +16%, Anavex Life Sciences AVXL +15%, MediciNova MNOV +14%, Aytu Biopharma (AYTU) +14%, Applied Molecular Transport (AMTI) +8%.Losers: Aptevo Therapeutics (APVO) -18%, Intec Pharma (NTEC) -16%, Conformis ...

Aptevo Therapeutics (APVO) has initiated the expansion phase of the company's APVO436 study, in adult patients with acute myeloid leukemia ((AML)), with a multi-center, multi-arm trial using the active recommended dose.The active recommended dose was identified in the dose escalation phase ((...

Initiates Multi-Center, Multi-Arm Trial Using Active Dose Identified in the Dose Escalation Phase of the Trial SEATTLE, WA / ACCESSWIRE / May 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ...

Aptevo Therapeutics ([[APVO]] +3.8%) shared positive data from a Phase 1 dose-escalation study designed to evaluate APVO436 in the treatment of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS).The trial involving 46 patients with AML or myelodysplastic syndromes, met i...

Dose Escalation Study of APVO436 Shows Favorable Safety Profile and No Severe Neutropenia, a Potentially Life-threatening Side Effect, Reported in a Significant Number of Patients Receiving CD123-Targeting Drugs Dosing Level Established For Advanced Clinical Trials SEATTLE, WA / A...

Aptevo Therapeutics (APVO): Q1 GAAP EPS of -$1.74 misses by $0.12.Revenue of $2.42M misses by $10.65M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.12, misses on revenue

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Dosing in Cohort 10 Ongoing SEATTLE, WA / ACCESSWIRE / May 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology ...

SEATTLE, WA / ACCESSWIRE / April 9, 2021 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR TM and ADAPTIR-FLEX TM platform technologies, today announced that it will p...

Aptevo Therapeutics (APVO): FY GAAP EPS of -$5.23 misses by $0.66.Revenue of $4.31M beats by $0.63M.Press Release For further details see: Aptevo Therapeutics EPS misses by $0.66, beats on revenue

Advances Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Enrollment in Cohort 10 Ongoing Completes Sale of RUXIENCE Royalty Payments for Up Front Plus Milestone Payments of up to $67.5 million; Amends Non-Dilutive Term Loan Ag...